Pharmaceutical product withdrawal: Attributions of blame and its impact on trust

Bunniran, Suvapun; McCaffrey, David J.; Bentley, John P.; Bouldin, Alicia S.

doi:10.1016/j.sapharm.2008.10.002

Cited by 10 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have found that nearly 3% of the drug products approved between 1975 and 1999 were ultimately withdrawn from use. From 2000 to 2006, six major pharmaceutical products were pulled from the market due to safety concerns [5]. Since 1998, the number of serious adverse drug events reported to FDA has been on a continual rise over the years.…”

Section: Introductionmentioning

confidence: 99%

Improvement of drug safety by the use of lipid-based nanocarriers

Lim

Banerjee

Önyüksel

2012

Journal of Controlled Release

261

142

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Improvement of drug safety by the use of lipid-based nanocarriers

Lim

Banerjee

Önyüksel

2012

Journal of Controlled Release

261

142

View full text Add to dashboard Cite

“…There is experimental evidence that supports these negative responses by consumers. For example, Bunniran et al (2009) study trust and blame due to the withdrawal of pharmaceutical products as a result of safety related concerns. They found that consumers taking the withdrawn drug or those taking another drug within the same class were highly likely to blame pharmaceutical companies and the FDA.…”

Section: Adverse Regulatory Eventsmentioning

confidence: 99%

Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling

Higgins¹,

Yan

Chatterjee

2021

Research Policy

View full text Add to dashboard Cite

We provide causal evidence that regulation induced product shocks significantly impact aggregate demand and firm performance in pharmaceutical markets. Event study results suggest an average loss between $569 million and $882 million. Affected products lose, on average, $186 million over their remaining effective patent life. This leaves a loss of between $383 million and $696 million attributable to declines in future innovation. Our findings complement research that shows drugs receiving expedited review are more likely to suffer from regulation induced product shocks. Thus, it appears we may be trading off quicker access to drugs today for less innovation tomorrow. Results remain robust to variation across types of relabeling, market sizes, and levels of competition.

show abstract

“…According to PMLive and GlobalData, among the 20 top global sales pharmaceutical companies, majority are companies originated from United States and Europe (PMLive, 2017). As one of the most innovative and researchintensive industries in the United States, pharmaceutical firms are constantly facing pressures from the governments and stakeholders (Bunniran, McCaffrey, Bentley, & Bouldin , 2009). From a molecule concept or idea discovery, to experiments, research & development, clinical trials, to obtaining approval from FDA and finally marketing the new drugs to the public, it takes approximately 10 to 15 years (Pilon & Elias, 2015).…”

Section: Introductionmentioning

confidence: 99%

“…While there are other factors that affect a patent duration, the common term of a new patent is 20 years from the date on which the application for the patent was filed in the United States, based on data published on FDA website (United States Food & Drug Administration, 2017). The cost to develop a new drug was estimated at $802 million (Bunniran, McCaffrey, Bentley, & Bouldin , 2009) in year 2009. However, the cost has increased enormously to approximately $2.6 billion in 2015 (Pilon & Elias, 2015).…”

Section: Introductionmentioning

confidence: 99%

A Study on Ethical Customer Management and Organizational Sustainability in Pharmaceutical Industry in Malaysia

Lee¹,

Arokiasamy²,

Marn³

2018

SHS Web Conf.

View full text Add to dashboard Cite

Pharmaceutical industry is not just a commercial business, their products are about life and death, and improving our life quality. This paper aims to study the ethical issues in customer management and how it contributes to organizational sustainability in Malaysia pharmaceutical industry. A quantitative research designed to collect primary data from questionnaire and secondary data from journal and articles focused on ethical customer management and pharmaceutical sustainability. The paper recognized 5 pillars; Direction, Posture, Organization, Behavior and Environment in DPOBE sustainability model and aligned them into ethical customer management in pharmaceutical which contribute positive impact towards organization sustainability in Malaysia. The findings of this paper serves as a guideline to pharmaceutical customer service agents in Malaysia SSC. It emphasizes the importance of ethical customer management and its impact to organization sustainability.

show abstract

Pharmaceutical product withdrawal: Attributions of blame and its impact on trust

Cited by 10 publications

References 23 publications

Improvement of drug safety by the use of lipid-based nanocarriers

Improvement of drug safety by the use of lipid-based nanocarriers

Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling

A Study on Ethical Customer Management and Organizational Sustainability in Pharmaceutical Industry in Malaysia

Contact Info

Product

Resources

About